Zehua He

He is a hepatic surgeon, currently, focuses on the application of Artificial Intelligence and Bioinformatics in the clinical diagnosis and treatment of liver cancer.

1. Zehua He , et al. Hepatocellular carcinoma subtypes based on metabolic pathways reveals potential therapeutic targets. Front Oncol. 2023, 13: 1086604.

2. Zehua He, et al. Artificial Intelligence Algorithm in Classification and Recognition of Primary Hepatic Carcinoma Images under Magnetic Resonance Imaging. Contrast Media & Molecular Imaging. 2022, 2022:1-11.

3. Zehua He , et al. Expressions of miR-23a and glucose transporter 1 in primary hepatocellular carcinoma tissues andtheir clinical significance. IntJ Clin Exp Med. 2020, 13(3): 1474-1483.

4. Zehua He , et al. Letter: cytokeratin-18 as a biomarker of hepatocellular carcinoma regression after transarterial chemoembo lization. Alimentary Pharmacology and Therapeutics. 2017, 45(1): 183-184.

5. Zehua He , et al. Mogroside V promotes the expression of LncRNA TUG1 and stimulates the proliferation and differentiation of osteoblasts. Chinese Tissue Engineering Research. 2020, 24(26): 4129-4134.

6. Zehua He , et al. Microwave ablation of liver cancer: An updated review. Shijie Huaren Xiaohua Zazhi. 2020, 28(10): 371-377.

7. Zehua He , et al. Endoscopic characteristics of bile duct lesions and duodenal papilla in patients with bile duct stones and pneumatosis. Shijie Huaren Xiaohua Zazhi. 2018, 26(7): 465-473.

8.Yang, Yu Feng, Zhang, Xi Ying, Yang, Mei, He, Ze Hua , et al. Prognostic Role of Nucleophosmin in Colorectal Carcinomas. Asian Pacific Journal of Cancer Prevention. 2014, 15(5): 2021-2026.

9. Participated in a 2023 Guangx Key R&D Program (No. 2023AC11022)，CI

10. Participated in a 2023 Guangxi Science and Technology R&D Program (No. 2023JJA140280), CI

11. Participated in a 2022 Guangxi Science and Technology R&D Program (No. 22AC21066), CI

12. Participated in a 2013 National Natural Science Foundation of China Project(No. 81260088), CI